THE SMART TRICK OF ABBV-744 PRECLINICAL STUDIES AND RESULTS THAT NOBODY IS DISCUSSING

In Segment C, members will obtain ABBV-744 and oral navitoclax. In Phase D, participants will get ABBV-744 and ruxolitinib. Contributors will obtain treatment until eventually disorder progression or even the participants are not able to tolerate the study drugs.- Participant eaten grapefruit or grapefruit solutions within 3 times prior to the firs